Home » Newsletters » BioWorld

BioWorld

April 18, 2011

View Archived Issues

Academia-Fueled R&D Helps Gilead's Move into Oncology

Money Raised Year to Date

Money Raised By Biotech in 2011

Week in Review

Word on the Street

Week in Washington

FDA Approvals in March

Phase I Clinical Trials Update: March 2011

Phase II Clinical Trials Update: March 2011

Phase III Clinical Trials Update: March 2011

Non-U.S. Clinical Trials & Regulatory Actions: March 2011

FDA Submissions, Approvals & Other Actions: March 2011

Stock Gainers and Losers For The Week

BioWorld Stock Report For Public Biotechnology Companies

Big Rewards, Bigger Risks? The Truth About Antibodies

It's no secret that monoclonal antibodies (mAbs) have been hot biotech property for a while. Read More

IPO Pricing, Shares Offered: It's a Numbers Game

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Hematopoietic stem cell research points to leukemia’s early roots
BioWorld Science
Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
Molecular signatures show subtypes in neurodegenerative diseases
BioWorld Science
Parkinson’s disease is a progressive neurodegenerative disorder best known for its motor symptoms. However, a proportion of patients also develop dementia as the...
More than two to tango: multispecifics at ESMO TAT
BioWorld Science
Multispecifics took center stage at this year’s ESMO TAT, emerging as one of the hottest trends in oncology research. Unlike traditional small-molecule drugs or...